[Adrenergic therapy and vigilance: beta-2 sympathomimetic aerosols in asthma].
It has been established that the use of beta-2 sympathomimetic aerosols is a safe and efficacious treatment of asthma. Unexpected cases of sudden death amongst insufficiently-treated patients or patients who stopped their treatment are not linked with the use of these drugs. To assess the risk of possible "receptor desensitization" it is necessary to notify these accidents to the Committee on Safety of Drugs and to take into consideration the opposite results of further administration and termination of treatment.
D000318:Adrenergic beta-Agonists / Q000009:adverse effects*; D000336:Aerosols / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D012307:Risk Factors
D000318:Adrenergic beta-Agonists; D000336:Aerosols
Médicaments adrénergiques et pharmacovigilance: les aérosols de bêta-2 sympathomimétiques dans l'asthme.